Dose Variation To Critical Points In Low Dose Rate Intracavitary Brachytherapy Of Cervical Cancer As Justification For Incident Learning

  • Eric C.D.K. Addison Department of Physics, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana Oncology Directorate, Komfo Anokye Teaching Hospital, Kumasi, Ghana Department of Medical Physics, Graduate School of Nuclear and Allied Sciences, University of Ghana
  • Joseph Adom Department of Physics, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana Oncology Directorate, Komfo Anokye Teaching Hospital, Kumasi, Ghana
  • Francis Hasford Department of Medical Physics, Graduate School of Nuclear and Allied Sciences, University of Ghana.
  • John H. Amuasi Department of Medical Physics, Graduate School of Nuclear and Allied Sciences, University of Ghana
Keywords: Low dose rate (LDR) Brachytherapy (BT), Cervical cancer, Intracavitary Brachytherapy Treatment

Abstract

Background: Low Dose Rate (LDR) brachytherapy necessitates a more extended treatment duration. This technique maintains the patient on the treatment machine for a longer length of time, which may cause changes in the applicators' position due to vaginal packing soaking and patient movement for incident learning justification.

Objective: The purpose of this study is to evaluate pre- and post-dosage variation to points 'A' and 'B,' as well as vital organs (i.e. bladder and rectum), for low dose rate (LDR) brachytherapy at Komfo Anokye Teaching Hospital and justify the need for incident learning system.

Method: Forty (40) patients with invasive cervical cancer were treated with LDR brachytherapy equipment (A Curietron Cesium Manuel (AMRA)-France, CA 98.22) to point 'A' at doses ranging from 30 to 35 Gy. Adult patients selected for the study ranged from 25 to 60 years simulated. For each patient, orthogonal images of anterior-posterior (AP) and (LAT) were taken by positioning the patient on the Varian Acuity Simulator Couch at 00 and 900, respectively, and two sets of orthogonal images (before and after treatment), in each case, were considered. The treatment was then planned using the AP and LAT images obtained based on the four arrangements used, namely 1-2-5, 1-3-5, 1-4-5, and 1-5. The treatment planning system used for the study was the Prowess Panther system 4.6.

Results: The dosage disparity at point 'A' was determined to be 1.16 per cent, which is highly commendable compared to previous research that established dose variations of 2%, 35%, 8%, and 20%. In this study, the dosage variation at point B was 0.75 per cent. The bladder and rectum had average alterations of 2.32 per cent and 0.30 per cent, respectively.

Conclusion: The difference observed between prescribed, and deposited dosage was 2.11 per cent for quality assurance and incident learning reasons. Unrealistic expectations, reliance on reminders and quick remedies, and faults in the systemic view of failure were discovered and addressed as managerial issues. It is critical not to underestimate these difficulties because they are frequently significantly more severe than the technical issues being addressed. Incident issues were not recorded per patients under review, but near misses and non-conformance were observed. The geometric variances between the Intracavitary Brachytherapy Treatment (ICBT) applicators and the essential organs change during the treatment process, resulting in dosage changes. Does variance is within the required standard limits; it can be stated that Komfo Anokye Teaching Hospital's practice satisfies the international standard and is an intrusion into the Directorate Incident Learning System.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

PlumX Statistics

References

1. Adams, A. R., Nortey, P. A., Dortey, B. A., Asmah, R. H., & Wiredu, E. K. (2019). Cervical Human Papillomavirus Prevalence, Genotypes, and Associated Risk Factors among Female Sex Workers in Greater Accra, Ghana. Journal of Oncology, 2019. https://doi.org/10.1155/2019/8062176
2. Adewole, I.F., Benedet, J.L., Crain, B.T. & Follen, M.2005. Evolving a strategic approach to cervical cancer control in Africa. Gynecologic Oncology 99, S209-S212.
3. Chaffer C. L., Weinberg R. A. (2011): A perspective on cancer cell metastasis. Science; 331: 1559-1564.
4. Corn W, Galvin D, Soffen M et al. Positional stability ofsources during LDR brachytherapy for cervical carcinoma.Int J RadiatOncolBiolPhys1993; 26: 513-518.
5. Denny, L. 2010. Cervical cancer in South Africa: An overview of current status and prevention
strategies. CME Feb. 28(2):70-73.
6. Domfeh A. B., WireduE. K., AdjeiA. A., Ayeh-KumiP. F. K., AdikuT. K., TetteyY., Gyasi R. K. and ArmahH. B. 2008 Cervical Human Papillomavirus Infection in Accra, Ghana. Ghana Medical JournalVolume 42, Number 2, pp 72 – 78
7. Hanahan D. & Weinberg R. (2001). The hallmarks of cancer. Cell ;100: 57-70.
8. Kohn LT, Corrigan JM, Donaldson MS. To Err Is Human: Building a Safer Health System, Vol. 627. Washington, D. C.: National Academies Press; 2000.
9. Koushik K., Bilimagga R., Rao N., JanakiM.G., Ponni A., RajeevA.G. (2010) Positional variation of applicators during low doserate intracavitary brachytherapy for cervical cancer:a prospective study. Journal Contemporary Brachytherapy 2010; 2, 3: 93-97 DOI: 10.5114/jcb.2010.16919
10. Leaver, D. & Labonte, G. 2010. HPV and cervical cancer. Radiation therapist, 19(1):27-44
Leedy, P. D. &Ormrod, J. E. 2005. Practical research planning & design, 8th ed. New Jersey:Pearson.
11. Ljunggren A, Swyman D, Herby L et al. (1987)An assessment of calculated doses in intracavitary gynecological radiotherapy. MedDosim; 12: 15-17
12. Makin, M.S. & Kamanu, C.I. 2010. Prevention and treatment of cervical cancer in Africa II Surgery in Africa-Monthly Review.
13. Nag, S., Cardenes, H., Chang, S., Das, I. J., Erickson, B., Ibbott, G. S., Varia, M. (2004). Proposed guidelines for image-based intracavitary brachytherapy for cervical carcinoma: report from Image-Guided Brachytherapy Working Group. International Journal of Radiation Oncology Biology Physics, 60(4), 1160-1172.
14. Parkin D.M., Ferlay J., Hamdi-Cherif M., Sitas F.,Thomas J.O., Wabinga H. and Whelan S.L. Cancerin Africa: Epidemiology and Prevention. 4.3 Cervix Cancer. IARC Scientific Publications 2003; No 153: Lyon: IARC Press, pp 268–276.
15. Pham T, Chen Y, Rouby E et al. Changes in HDR tandem and ovoid applicator positions during treatment in an unfixed brachytherapy system. Radiology 1998; 206: 525-531.
16. Pollack LA, Rowland JH, Crammer C, Stefanek M: Introduction: charting the landscape of cancer survivors' health-related outcomes and care. Cancer 2009; 115: 4265-4269.
17. Sheybani A., Tennapel M. J., Sun W., Kim Y., Rockey W. M. (2013) Dose-Volume Effect of Bladder and Rectal Filling during Intracavitary High-Dose-Rate Brachytherapy. Brachytherapy 12: S11-S77
18. Viswanathan, A.N. & Thomadsen, B. Undated. (2009) American Brachythterapy Society (ABS) cervicalcancer task group. Reviewed by: Erickson, B. Gaffney, D. Small, W. & Hsu, I.
19. WHO (World Health Organization). 2012. “Prevention of Cervical Cancer through Screening and Using Visual Inspection with Acetic Acid (VIA) and Treatment with Cryotherapy.” WHO, Geneva.
20. WHO, 2008. World cancer report 2008. Geneva: Published by the International Agency for
Research on Cancer. World Health Organization (WHO). Available:
http://www.iarc.fr/en/publications/pdfs-online/wrc/2008/index.pdf. [4/05/2010]
21. WHO, 2020 Report on cancer: setting priorities, investing wisely and providing care for all. Geneva: World Health Organization (WHO). Licence: CC BY-NC-SA 3.0 IGO.
Published
2022-01-31
How to Cite
Addison, E. C., Adom, J., Hasford, F., & Amuasi, J. H. (2022). Dose Variation To Critical Points In Low Dose Rate Intracavitary Brachytherapy Of Cervical Cancer As Justification For Incident Learning. European Scientific Journal, ESJ, 18(3), 48. https://doi.org/10.19044/esj.2022.v18n3p48
Section
ESJ Natural/Life/Medical Sciences